原发性乳腺癌外周血EGFRmRNA及CK20mRNA联合检测的研究

The study of detection of epidermal growth factor receptor and cytokeratin-20mRNA in peripheral blood of primary breast cancer patients by reverse transcription polymerase chain reaction

目的检测乳腺癌患者外周血中表皮生长因子受体(epidermal growthfactor receptor,EGFR)及细胞角蛋白20(cytokeratin20 CK20)并分析其临床病理联系。方法应用逆转录聚合酶链反应(RT-PCR)检测44例乳腺癌及30例女性健康人外周血CK20 mRNA及EGFRmRNA。结果300例健康对照组外周血CK20mRNA及EGFRmRNA均为阴性。患者组EGFR及CK20mRNA表达阳性分别为(20/44,16/44)。EGFRmRNA及CK20mRNA表达阳性在TNM分期中为Ⅰ期(2/6,1/6),Ⅱ期(3/12,2/12),Ⅲ期(11/18,10/18)及IV期(4/8,3/8),(P<0.05,Ⅰ,ⅡvsⅢ,Ⅳ);与对照组比较有显著差异。结论RT-PCR方法检测乳腺癌患者外周血中EGFRmRNAand CK20mRNA表达与其临床及病理分期相关。此两项指标联合检测可作为乳腺癌诊断、治疗及预后的参考指标。

Objective To explore the eytokerafin 20 （CK20） and epidermal growth factor receptor（EGFR） in peripheral blood of the patients with breast cancer and evaluated the clinical significance.Methods The expression of EGFRmRNA and CK20mRNA in peripheral blood was examined by reverse transcription polymerase chain reaction （RT-PCR） in 44 patients with breast cancer and30 normal controls. Results In peripheral blood from 30 healthy donors, neither EGFRmRNA nor CK20mRNA was expressed. The EGFRmRNA and CK20mRNA positive were detected in breast（20/44, 16/44） .The expression of EGFRmRNA and CK20mRNA in TNM clinical stage were found in Ⅰ （2/6,1/6 in breast cancer）, Ⅱ （3/12,2/12 in breast cancer）, Ⅲ 11/18,10/18 in breast cancer ） and Ⅳ （4/8,3/8 in breast cancer）, （ P 〈 0.05, Ⅰ , Ⅱ vs Ⅲ, Ⅳ ）. There were difference of the EGFR and CK20 expression rate hetween the patients in Ⅰ and Ⅱ and Ⅲ and Ⅳ clinical stage. Conclusion The expression of EGFRmRNA and CK20mRNA in pc. ripheral blood of patients with breast eancer correlated with clinical stage. These data suggested that the detection of EGFR and CK20mRNA by using RT-PCR are useful marker of circulating tumor cell and will he helpful in assessing prognosis,tailoring therapy, or developing new strategies.